Exploring new methods for creating complex molecules to aid in drug discovery
New opportunities for the Cope rearrangement: methods, modular synthesis, and applications in drug discovery
['FUNDING_OTHER'] · UNIVERSITY OF MINNESOTA · NIH-10843128
This study is working on improving a chemical process that helps create important building blocks for new medicines, which could eventually lead to better treatments for patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MINNESOTA (nih funded) |
| Locations | 1 site (MINNEAPOLIS, UNITED STATES) |
| Trial ID | NIH-10843128 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the Cope rearrangement, a chemical reaction that can be used to synthesize complex molecules important for drug discovery. The team aims to develop new methods that make this transformation more versatile and applicable in creating diverse chemical compounds. By addressing challenges related to the thermodynamics and kinetics of the reaction, they hope to unlock its potential for producing valuable drug candidates. Patients may benefit indirectly as these advancements could lead to the development of new therapies.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research are individuals with conditions that could be treated by new drug therapies developed from these chemical advancements.
Not a fit: Patients who are not seeking new treatment options or those with conditions that do not align with the focus of the drug discovery efforts may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to the creation of new drugs that are more effective in treating various diseases.
How similar studies have performed: Other research has shown success with similar chemical synthesis approaches, indicating a promising avenue for drug discovery.
Where this research is happening
MINNEAPOLIS, UNITED STATES
- UNIVERSITY OF MINNESOTA — MINNEAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: GRENNING, ALEXANDER JAMES — UNIVERSITY OF MINNESOTA
- Study coordinator: GRENNING, ALEXANDER JAMES
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.